Entero Healthcare Solutions Limited (NSE: ENTERO) and Remus Pharmaceuticals Limited (NSE: REMUS) are both listed in the Pharmaceutical Product Distribution industry. Entero Healthcare Solutions has a market capitalisation of ₹6,846 Cr and Remus Pharmaceuticals ₹979 Cr, as of 9 Nov 2026. Their P/E ratios are 59.5 and 26.5 respectively. Return on equity is 8.28% for Entero Healthcare Solutions and 13.78% for Remus Pharmaceuticals. Over one year, Entero Healthcare Solutions's share price is up 89.2% and Remus Pharmaceuticals's is up 11.2%.
| Metric | Entero Healthcare Solutions | Remus Pharmaceuticals |
|---|---|---|
| NSE Symbol | ENTERO | REMUS |
| BSE Code | 544122 | — |
| Share Price | ₹2,089.00 | ₹831.00 |
| Market Cap | ₹6,846 Cr | ₹979 Cr |
| P/E Ratio | 59.5 | 26.5 |
| Return on Equity | 8.28% | 13.78% |
| Return on Assets | 4.41% | 6.67% |
| Dividend Yield | — | 0.12% |
| Beta (1Y) | 0.14 | 0.45 |
| 1-Year Price Change | +89.2% | +11.2% |
| 3-Month Price Change | +58.8% | -5.0% |
| 52-Week Range | ₹944.00 – ₹2,137.60 | ₹580.00 – ₹1,039.00 |
| Latest Quarter | Q2 FY27 | — |
| Quarterly Revenue | ₹2,087 Cr | — |
| Quarterly Net Profit | ₹61 Cr | — |
| Net Margin | 2.9% | — |
| EPS (Basic, Quarter) | ₹10.47 | — |
| Results Basis | consolidated | — |
| Headquarters | Mumbai, Maharashtra | Ahmedabad, Gujarat |
The figures sit side by side and are not ranked. Quarterly figures are in ₹ crore, parsed from each company's exchange filing (XBRL); the two companies' latest quarters can differ.
Entero Healthcare Solutions Limited engages in the trading of pharmaceutical and surgical products in India. The company offers a range of pharmaceuticals and other healthcare products to retail pharmacies and healthcare practitioners; and healthcare products, including pharmaceutical and nutraceutical products and vaccines; medical devices, such as orthopaedic implants and coronary stents; and hospital consumables comprising examination and surgical gloves, syringes, needles, and sutures to hospitals and clinics. It also provides private label products under the Entero Surgicals private label…
Remus Pharmaceuticals Limited engages in the marketing, trading, and distribution of pharmaceuticals products and allied products in India and internationally. It is involved in trading of active pharmaceutical ingredient, as well as provides technical and consultancy services to various distributors and contract manufacturing services. The company offers tablet, hard and soft gelatine capsules, liquid and lyophilized injections, as well as pre-filled syringe, infusions, inhalers, nebulizers, nasal sprays and solutions, eye drops, creams, gels, ointments, suspensions, oral solutions and suspen…
Entero Healthcare Solutions has a market capitalisation of ₹6,846 Cr, against ₹979 Cr for Remus Pharmaceuticals as of 9 Nov 2026, about 7.0 times the size by market cap.
Entero Healthcare Solutions has a P/E of 59.5 and Remus Pharmaceuticals a P/E of 26.5 as of 9 Nov 2026.
Entero Healthcare Solutions has a return on equity of 8.28% and Remus Pharmaceuticals 13.78%.
Entero Healthcare Solutions's share price is up 89.2% over one year and Remus Pharmaceuticals's is up 11.2%.
Both are classified under Health Care Providers and Services > Health Care Distributors > Pharmaceutical Product Distribution on FinBizNet.
No. The page lays the two companies' published figures side by side and draws no conclusion from them. It is descriptive market data, not investment advice.
Data as of 9 Nov 2026. Descriptive market data only — not investment advice.